Cargando…

S214: DISEASE-MODIFYING ACTIVITY OF NAVTEMADLIN (NVTM) CORRELATED WITH SURVIVAL OUTCOMES IN JANUS KINASE INHIBITOR (JAKI) RELAPSED OR REFRACTORY (R/R) MYELOFIBROSIS (MF) PATIENTS (PTS)

Detalles Bibliográficos
Autores principales: Vachhani, Pankit, Perkins, Andrew, Mascarenhas, John, Al-Ali, Haifa Kathrin, Kiladjian, Jean-Jacques, Cerquozzi, Sonia, Dybko, Jaroslaw, Delgado, Regina Garcia, Rivas, Jesus Hernández, Hebart, Holger, Huang, Zhuying, Krejsa, Cecile, Qamoos, Hope, Mcgreivy, Jesse, Rothbaum, Wayne P., Verstovsek, Srdan, Vannucchi, Alessandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428410/
http://dx.doi.org/10.1097/01.HS9.0000967768.05521.ca
_version_ 1785090462393040896
author Vachhani, Pankit
Perkins, Andrew
Mascarenhas, John
Al-Ali, Haifa Kathrin
Kiladjian, Jean-Jacques
Cerquozzi, Sonia
Dybko, Jaroslaw
Delgado, Regina Garcia
Rivas, Jesus Hernández
Hebart, Holger
Huang, Zhuying
Krejsa, Cecile
Qamoos, Hope
Mcgreivy, Jesse
Rothbaum, Wayne P.
Verstovsek, Srdan
Vannucchi, Alessandro
author_facet Vachhani, Pankit
Perkins, Andrew
Mascarenhas, John
Al-Ali, Haifa Kathrin
Kiladjian, Jean-Jacques
Cerquozzi, Sonia
Dybko, Jaroslaw
Delgado, Regina Garcia
Rivas, Jesus Hernández
Hebart, Holger
Huang, Zhuying
Krejsa, Cecile
Qamoos, Hope
Mcgreivy, Jesse
Rothbaum, Wayne P.
Verstovsek, Srdan
Vannucchi, Alessandro
author_sort Vachhani, Pankit
collection PubMed
description
format Online
Article
Text
id pubmed-10428410
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-104284102023-08-17 S214: DISEASE-MODIFYING ACTIVITY OF NAVTEMADLIN (NVTM) CORRELATED WITH SURVIVAL OUTCOMES IN JANUS KINASE INHIBITOR (JAKI) RELAPSED OR REFRACTORY (R/R) MYELOFIBROSIS (MF) PATIENTS (PTS) Vachhani, Pankit Perkins, Andrew Mascarenhas, John Al-Ali, Haifa Kathrin Kiladjian, Jean-Jacques Cerquozzi, Sonia Dybko, Jaroslaw Delgado, Regina Garcia Rivas, Jesus Hernández Hebart, Holger Huang, Zhuying Krejsa, Cecile Qamoos, Hope Mcgreivy, Jesse Rothbaum, Wayne P. Verstovsek, Srdan Vannucchi, Alessandro Hemasphere Oral Sessions Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10428410/ http://dx.doi.org/10.1097/01.HS9.0000967768.05521.ca Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially.
spellingShingle Oral Sessions
Vachhani, Pankit
Perkins, Andrew
Mascarenhas, John
Al-Ali, Haifa Kathrin
Kiladjian, Jean-Jacques
Cerquozzi, Sonia
Dybko, Jaroslaw
Delgado, Regina Garcia
Rivas, Jesus Hernández
Hebart, Holger
Huang, Zhuying
Krejsa, Cecile
Qamoos, Hope
Mcgreivy, Jesse
Rothbaum, Wayne P.
Verstovsek, Srdan
Vannucchi, Alessandro
S214: DISEASE-MODIFYING ACTIVITY OF NAVTEMADLIN (NVTM) CORRELATED WITH SURVIVAL OUTCOMES IN JANUS KINASE INHIBITOR (JAKI) RELAPSED OR REFRACTORY (R/R) MYELOFIBROSIS (MF) PATIENTS (PTS)
title S214: DISEASE-MODIFYING ACTIVITY OF NAVTEMADLIN (NVTM) CORRELATED WITH SURVIVAL OUTCOMES IN JANUS KINASE INHIBITOR (JAKI) RELAPSED OR REFRACTORY (R/R) MYELOFIBROSIS (MF) PATIENTS (PTS)
title_full S214: DISEASE-MODIFYING ACTIVITY OF NAVTEMADLIN (NVTM) CORRELATED WITH SURVIVAL OUTCOMES IN JANUS KINASE INHIBITOR (JAKI) RELAPSED OR REFRACTORY (R/R) MYELOFIBROSIS (MF) PATIENTS (PTS)
title_fullStr S214: DISEASE-MODIFYING ACTIVITY OF NAVTEMADLIN (NVTM) CORRELATED WITH SURVIVAL OUTCOMES IN JANUS KINASE INHIBITOR (JAKI) RELAPSED OR REFRACTORY (R/R) MYELOFIBROSIS (MF) PATIENTS (PTS)
title_full_unstemmed S214: DISEASE-MODIFYING ACTIVITY OF NAVTEMADLIN (NVTM) CORRELATED WITH SURVIVAL OUTCOMES IN JANUS KINASE INHIBITOR (JAKI) RELAPSED OR REFRACTORY (R/R) MYELOFIBROSIS (MF) PATIENTS (PTS)
title_short S214: DISEASE-MODIFYING ACTIVITY OF NAVTEMADLIN (NVTM) CORRELATED WITH SURVIVAL OUTCOMES IN JANUS KINASE INHIBITOR (JAKI) RELAPSED OR REFRACTORY (R/R) MYELOFIBROSIS (MF) PATIENTS (PTS)
title_sort s214: disease-modifying activity of navtemadlin (nvtm) correlated with survival outcomes in janus kinase inhibitor (jaki) relapsed or refractory (r/r) myelofibrosis (mf) patients (pts)
topic Oral Sessions
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428410/
http://dx.doi.org/10.1097/01.HS9.0000967768.05521.ca
work_keys_str_mv AT vachhanipankit s214diseasemodifyingactivityofnavtemadlinnvtmcorrelatedwithsurvivaloutcomesinjanuskinaseinhibitorjakirelapsedorrefractoryrrmyelofibrosismfpatientspts
AT perkinsandrew s214diseasemodifyingactivityofnavtemadlinnvtmcorrelatedwithsurvivaloutcomesinjanuskinaseinhibitorjakirelapsedorrefractoryrrmyelofibrosismfpatientspts
AT mascarenhasjohn s214diseasemodifyingactivityofnavtemadlinnvtmcorrelatedwithsurvivaloutcomesinjanuskinaseinhibitorjakirelapsedorrefractoryrrmyelofibrosismfpatientspts
AT alalihaifakathrin s214diseasemodifyingactivityofnavtemadlinnvtmcorrelatedwithsurvivaloutcomesinjanuskinaseinhibitorjakirelapsedorrefractoryrrmyelofibrosismfpatientspts
AT kiladjianjeanjacques s214diseasemodifyingactivityofnavtemadlinnvtmcorrelatedwithsurvivaloutcomesinjanuskinaseinhibitorjakirelapsedorrefractoryrrmyelofibrosismfpatientspts
AT cerquozzisonia s214diseasemodifyingactivityofnavtemadlinnvtmcorrelatedwithsurvivaloutcomesinjanuskinaseinhibitorjakirelapsedorrefractoryrrmyelofibrosismfpatientspts
AT dybkojaroslaw s214diseasemodifyingactivityofnavtemadlinnvtmcorrelatedwithsurvivaloutcomesinjanuskinaseinhibitorjakirelapsedorrefractoryrrmyelofibrosismfpatientspts
AT delgadoreginagarcia s214diseasemodifyingactivityofnavtemadlinnvtmcorrelatedwithsurvivaloutcomesinjanuskinaseinhibitorjakirelapsedorrefractoryrrmyelofibrosismfpatientspts
AT rivasjesushernandez s214diseasemodifyingactivityofnavtemadlinnvtmcorrelatedwithsurvivaloutcomesinjanuskinaseinhibitorjakirelapsedorrefractoryrrmyelofibrosismfpatientspts
AT hebartholger s214diseasemodifyingactivityofnavtemadlinnvtmcorrelatedwithsurvivaloutcomesinjanuskinaseinhibitorjakirelapsedorrefractoryrrmyelofibrosismfpatientspts
AT huangzhuying s214diseasemodifyingactivityofnavtemadlinnvtmcorrelatedwithsurvivaloutcomesinjanuskinaseinhibitorjakirelapsedorrefractoryrrmyelofibrosismfpatientspts
AT krejsacecile s214diseasemodifyingactivityofnavtemadlinnvtmcorrelatedwithsurvivaloutcomesinjanuskinaseinhibitorjakirelapsedorrefractoryrrmyelofibrosismfpatientspts
AT qamooshope s214diseasemodifyingactivityofnavtemadlinnvtmcorrelatedwithsurvivaloutcomesinjanuskinaseinhibitorjakirelapsedorrefractoryrrmyelofibrosismfpatientspts
AT mcgreivyjesse s214diseasemodifyingactivityofnavtemadlinnvtmcorrelatedwithsurvivaloutcomesinjanuskinaseinhibitorjakirelapsedorrefractoryrrmyelofibrosismfpatientspts
AT rothbaumwaynep s214diseasemodifyingactivityofnavtemadlinnvtmcorrelatedwithsurvivaloutcomesinjanuskinaseinhibitorjakirelapsedorrefractoryrrmyelofibrosismfpatientspts
AT verstovseksrdan s214diseasemodifyingactivityofnavtemadlinnvtmcorrelatedwithsurvivaloutcomesinjanuskinaseinhibitorjakirelapsedorrefractoryrrmyelofibrosismfpatientspts
AT vannucchialessandro s214diseasemodifyingactivityofnavtemadlinnvtmcorrelatedwithsurvivaloutcomesinjanuskinaseinhibitorjakirelapsedorrefractoryrrmyelofibrosismfpatientspts